Paying for care
Ask for the medicine, visits, tests and follow-up costs together. Keep introductory terms beside the regular price.
The source notes used here were recorded on or before September 26, 2026. Later changes may be missing.
The online-service pages reviewed on September 26, 2026 commonly used a monthly membership, with the medicine charged separately.
Request a written breakdown: the assessment, repeat visits, medicine, tests and delivery. Ask which parts continue to be charged if treatment is delayed or declined.
Read the renewal and cancellation terms before comparing a short offer with an ongoing plan.
The manufacturer’s semaglutide self-pay offers spanned $149 to $499 a month in the September 26, 2026 record, with product and strength setting the price.
For Ozempic and Wegovy injections, a new patient paying cash could get the first monthly supply for $199 and the second for $199. The 0.25 mg strength qualifies, as does 0.5 mg. December 31, 2026 is the recorded deadline for this offer.
The letters mg stand for milligrams, a measure of the amount of medicine.
For the Ozempic offer, the recorded terms require US residence and an age of at least 18. People with insurance cannot ask the insurer to repay this cost or count it toward their deductible, the amount they pay before insurance starts paying.
The strengths here identify the price offers. Ask the prescriber which product fits your care and the service whether you qualify for its offer.
Once the introductory fills were used, the recorded Ozempic (semaglutide) injection offer charged either $349 or $499 a month, based on strength.
These medicine figures do not quote a complete care plan. Ask for the price attached to the exact product being discussed and the terms that apply to you.
As of September 26, 2026, ordinary Medicare drug coverage still excludes medicines used for weight loss alone.
Coverage for other medically accepted uses remains possible, with each Medicare plan’s own medicine list and prior approval process still deciding access.
The Medicare GLP-1 Bridge is temporary, with selected products available to eligible people. Their share of the medicine bill, called a copay, is $50 a month. The recorded closing date is December 31, 2027; the opening date was July 1, 2026.
The Bridge is open to adults aged 18 and over who meet its other conditions; being 80 does not by itself rule someone out. A prescription is needed. Payment also needs advance approval, called prior authorization.
Your Medicare drug plan must be one the programme accepts. Eligibility also depends on weight and health conditions when treatment began. Part D is Medicare’s medicine coverage. For 2026, the Bridge cannot be used if Medicare Part D has already covered your GLP-1 medicine that year.
Bring your records to the prescriber and compare them with the weight and health conditions in the linked Medicare information.
People with type 2 diabetes do not use the Bridge for that treatment. Instead, they ask their regular Medicare Part D drug plan about coverage for the diabetes medicine.
Wegovy injection and tablets are the semaglutide products included in the Bridge; Ozempic for weight loss is excluded.
Ask the plan to check the product, form and reason for treatment together. Ask what you would pay if coverage is refused.